There are currently 408 ongoing clinical trials involving Mild Cognitive Impairment
Of the 408 trials,157 trials are in Phase II
Furthermore, 133 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Mild Cognitive Impairment, a Central Nervous System disorder. The largest number of ongoing clinical trials for Mild Cognitive Impairment is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Mild Cognitive Impairment-related drug trials.
CuraSen Therapeutics Inc and Johns Hopkins University: The leading ongoing Mild Cognitive Impairment related clinical trial sponsors
CuraSen Therapeutics Inc and Johns Hopkins University are the top sponsors for Mild Cognitive Impairment-related ongoing clinical trials.
Wake Forest University Health Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Eisai Co Ltd and TauRx Therapeutics Ltd are among other notable clinical trial sponsors involved in Mild Cognitive Impairment. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward